Jason Butler

“First one, can you give any more color on the size or scope of the pilot study being conducted by the new LBO?”

“On the commercial side, obviously, it's only been a short period of time, but what are you already doing with Azurety to get them ready for the launch? You've obviously done a lot of pre-commercial work.”

“Just two things. can you tell us anything about patient attrition, any commercial patients who are no longer taking the drug and maybe a percentage there? And how did the end of our 2Q inventory compare to the end of 1Q?”

“Obvious first question, can you give us any color or insight into the growth rate we should expect from 2Q to 3Q? Can you maintain the growth rate you saw from 1Q to 2Q, or at least just in broad level, help us understand the trajectory we should expect here?”

“Hi, thanks for taking the questions, and congrats on the quarter and the progress with Papsunios. A couple from me. First of all, can you speak to the number of patients that have now received at least the first dose, and if you're now also seeing patients complete the full course of therapy?”